HIV Infections
Conditions
Keywords
people who inject drugs, men who have sex with men, HIV, India
Brief summary
This clinical trial will compare the effectiveness of integrated care centers vs. integrated care centers plus HIV patient treatment incentives for achieving HIV treatment targets among people who inject drugs and men who have sex with men in India. The investigators will also assess cost-effectiveness and barriers and facilitators to implementation through targeted mixed-methods approaches. This study is a model for improving HIV treatment outcomes in key populations in low to middle-income countries.
Detailed description
The trajectory of the HIV epidemic in coming decades will be determined by the degree to which we can identify infected persons and engage them in care - a point implicit in the ambitious UNAIDS 90-90-90 target, which sets 90% goals for HIV diagnosis, linkage of infected persons to sustained antiretroviral therapy (ART), and viral suppression in those treated. Meeting this target requires successful engagement of difficult to reach populations, such as people who inject drugs (PWID) and men who have sex with men (MSM), who bear a disproportionate share of the epidemic, particularly in low to middle income countries. Our team is nearing completion of a multi-site cluster-randomized trial in India to assess the effectiveness of integrated care centers (ICCs) for PWID and MSM compared to usual care. ICC process measures from the first year show robust uptake of HIV counseling and testing, the primary outcome for that trial, but slower than anticipated ART uptake. Demand-side interventions in public health (such as treatment incentives) can be particularly effective when paired with optimized treatment accessibility (i.e., supply). Consequently, the investigators propose to examine whether provision of HIV care and treatment incentives to ICC clients will improve overall utilization of the clinics and downstream HIV care continuum outcomes. The investigators propose a hybrid effectiveness-implementation design. This will include a 16-site, pair-matched cluster randomized trial to compare the effectiveness of adding of HIV care incentives to ICCs (ICC+) versus standard ICCs on HIV care continuum outcomes, including ART initiation, adherence and viral suppression. Effectiveness will be compared at the ICC level (from a cohort of HIV-infected ART-eligible clients followed in each ICC and process measures deriving from all ICC clients) and at the community-level through a cross-sectional sample accrued via respondent-driven sampling (RDS) 2 years after initiation of the intervention. Because PWID and MSM will be sampled independently from the ICCs in the RDS, it provides an opportunity to characterize outcomes like community viral load and HIV incidence, reflecting impact within the broader PWID/MSM communities. As an exploratory sub-aim, we will use a rigorous scientific design to assess the effects of withdrawing (vs. continuing) incentives beyond the initial intervention phase. Additionally, the investigators will determine the cost-effectiveness of the ICC+ intervention.
Interventions
Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
Sponsors
Study design
Intervention model description
Matched-pair cluster-randomized trial
Eligibility
Inclusion criteria
* Speaks Hindi, English, or local language * HIV-positive * Antiretroviral therapy (ART) naive or has used ART less than 12 months * Registered client at the local integrated care center (ICC), which serves either people who inject drugs (PWID) or men who have sex with men (MSM).
Exclusion criteria
* Not competent to provide informed consent or participate in the study. * Receives HIV care in the private sector * Plans to migrate in next 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants Surviving With Viral Suppression | 12 months | Viral Suppression defined as HIV RNA \<150 copies/mL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With Viral Suppression at One or More Follow-up Visits | 24 months | Proportion with viral suppression (HIV RNA \<150 copies/mL) at one or more follow-up visits |
| Antiretroviral Therapy (ART) Initiation | 12 months | Rate of ART initiation among those naive to ART at baseline. This is reported as the proportion of participants who initiated ART. |
| Proportion of Participants Surviving With Viral Suppression | 6 months | Viral suppression defined as HIV RNA \<150 copies/mL |
| ART Adherence | 12 months | Proportion of participants who had a medication possession ratio of 0.9 or higher after starting ART |
| Mortality | 12 months | All-cause mortality |
| Retention to HIV Care | 12 months | Proportion of participants who attended one or more visits to a government ART clinic in both the 0 to 6 month period and the 6 to 12 month period. |
Countries
India
Participant flow
Pre-assignment details
22 sites were considered for the trial and 16 were selected on the basis of high HIV prevalence. The 16 study sites were matched into pairs and randomized to incentives or usual care. Sites were matched according to key population (people who inject drugs or men who have sex with men) and HIV burden.
Participants by arm
| Arm | Count |
|---|---|
| PWID [Usual Care] People who inject drugs (PWID) in 4 sites assigned to usual care | 600 |
| PWID [Incentives] People who inject drugs (PWID) in 4 sites assigned to the incentives intervention | 600 |
| MSM [Usual Care] Men who have sex with men (MSM) in 4 sites assigned to usual care | 600 |
| MSM [Incentives] Men who have sex with men (MSM) in 4 sites assigned to the incentives intervention | 514 |
| Total | 2,314 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Censored due to COVID-19 | 481 | 471 |
| Overall Study | Death | 104 | 125 |
| Overall Study | Lost to Follow-up | 108 | 112 |
Baseline characteristics
| Characteristic | PWID [Usual Care] | PWID [Incentives] | MSM [Usual Care] | MSM [Incentives] | Total |
|---|---|---|---|---|---|
| Age, Continuous | 28 years | 30 years | 30 years | 32 years | 30 years |
| CD4 cell count | 391 cells/microliter | 384 cells/microliter | 314 cells/microliter | 276 cells/microliter | 347 cells/microliter |
| HIV RNA <150 copies/mL | 61 Participants | 153 Participants | 108 Participants | 138 Participants | 460 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 600 Participants | 600 Participants | 600 Participants | 514 Participants | 2314 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Secondary school education or beyond | 336 Participants | 381 Participants | 375 Participants | 352 Participants | 1444 Participants |
| Sex: Female, Male Female | 2 Participants | 152 Participants | 0 Participants | 0 Participants | 154 Participants |
| Sex: Female, Male Male | 598 Participants | 448 Participants | 600 Participants | 514 Participants | 2160 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 104 / 1,114 | 125 / 1,200 |
| other Total, other adverse events | 0 / 1,114 | 0 / 1,200 |
| serious Total, serious adverse events | 104 / 1,114 | 125 / 1,200 |
Outcome results
Proportion of Participants Surviving With Viral Suppression
Viral Suppression defined as HIV RNA \<150 copies/mL
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Proportion of Participants Surviving With Viral Suppression | 0.494 proportion of participants |
| Usual Care | Proportion of Participants Surviving With Viral Suppression | 0.353 proportion of participants |
Antiretroviral Therapy (ART) Initiation
Rate of ART initiation among those naive to ART at baseline. This is reported as the proportion of participants who initiated ART.
Time frame: 12 months
Population: This analysis includes only participants who had never started ART previously
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Antiretroviral Therapy (ART) Initiation | 0.721 Proportion of participants |
| Usual Care | Antiretroviral Therapy (ART) Initiation | 0.708 Proportion of participants |
ART Adherence
Proportion of participants who had a medication possession ratio of 0.9 or higher after starting ART
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | ART Adherence | 0.645 proportion of participants |
| Usual Care | ART Adherence | 0.463 proportion of participants |
Mortality
All-cause mortality
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Mortality | 0.051 Proportion of participants |
| Usual Care | Mortality | 0.068 Proportion of participants |
Proportion of Participants Surviving With Viral Suppression
Viral suppression defined as HIV RNA \<150 copies/mL
Time frame: 24 months
Population: Overall number of participants analyzed is equal to enrolled cohort minus participants who were censored at the 24-month visit due to COVID-related stoppage.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Proportion of Participants Surviving With Viral Suppression | 0.471 Proportion of participants |
| Usual Care | Proportion of Participants Surviving With Viral Suppression | 0.325 Proportion of participants |
Proportion of Participants Surviving With Viral Suppression
Viral suppression defined as HIV RNA \<150 copies/mL
Time frame: 18 months
Population: Overall number of participants analyzed is equal to enrolled cohort minus participants who were censored at the 18-month visit due to COVID-related stoppage.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Proportion of Participants Surviving With Viral Suppression | 0.497 Proportion of participants |
| Usual Care | Proportion of Participants Surviving With Viral Suppression | 0.358 Proportion of participants |
Proportion of Participants Surviving With Viral Suppression
Viral suppression defined as HIV RNA \<150 copies/mL
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Proportion of Participants Surviving With Viral Suppression | 0.509 Proportion of participants |
| Usual Care | Proportion of Participants Surviving With Viral Suppression | 0.365 Proportion of participants |
Proportion of Participants With Viral Suppression at One or More Follow-up Visits
Proportion with viral suppression (HIV RNA \<150 copies/mL) at one or more follow-up visits
Time frame: 24 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Proportion of Participants With Viral Suppression at One or More Follow-up Visits | 0.640 Proportion of participants |
| Usual Care | Proportion of Participants With Viral Suppression at One or More Follow-up Visits | 0.498 Proportion of participants |
Retention to HIV Care
Proportion of participants who attended one or more visits to a government ART clinic in both the 0 to 6 month period and the 6 to 12 month period.
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Incentives | Retention to HIV Care | 0.702 Proportion of participants |
| Usual Care | Retention to HIV Care | 0.664 Proportion of participants |